PT - JOURNAL ARTICLE AU - Ivana Pennisi AU - Ahmad Moniri AU - Nicholas Miscourides AU - Luca Miglietta AU - Nicolas Moser AU - Dominic Habgood-Coote AU - Jethro A. Herberg AU - Michael Levin AU - Myrsini Kaforou AU - Jesus Rodriguez-Manzano AU - Pantelis Georgiou TI - Discrimination of bacterial and viral infection using host-RNA signatures integrated in a lab-on-a-chip technology AID - 10.1101/2022.02.21.22271125 DP - 2022 Jan 01 TA - medRxiv PG - 2022.02.21.22271125 4099 - http://medrxiv.org/content/early/2022/02/22/2022.02.21.22271125.short 4100 - http://medrxiv.org/content/early/2022/02/22/2022.02.21.22271125.full AB - The unmet clinical need for accurate point-of-care (POC) diagnostic tests able to discriminate bacterial from viral infection demands a solution that can be used both within healthcare settings and in the field and that can also stem the tide of antimicrobial resistance. Our approach to solve this problem is to combine the use of Host-gene signatures with our Lab-on-a-chip (LoC) technology enabling low-cost LoC expression analysis to detect Infectious Disease.Host-gene expression signatures have been extensively study as a potential tool to be implemented in the diagnosis of infectious disease. On the other hand LoC technologies using Ion-sensitive field-effect transistor (ISFET) arrays, in conjunction with isothermal chemistries, are offering a promising alternative to conventional lab-based nucleic acid amplification instruments, owing to their portable and affordable nature. Currently, the data analysis of ISFET arrays are restricted to established methods by averaging the output of every sensor to give a single time-series. This simple approach makes unrealistic assumptions, leading to insufficient performance for applications that require accurate quantification such as RNA host transcriptomics. In order to reliably quantify host-gene expression on our LoC platform enabling the classification of bacterial and viral infection on chip, we propose a novel data-driven algorithm for extracting time-to-positive values from ISFET arrays. The algorithm proposed is based on modelling sensor drift with adaptive signal processing and clustering sensors based on their behaviour with unsupervised learning methods. Results show that the approach correctly outputs a time-to-positive for all the reactions, with a high correlation to RT-qLAMP (0.85, R2 = 0.98, p < 0.01), resulting in a classification accuracy of 100 % (CI, 95 - 100). By leveraging more advanced data processing methods for ISFET arrays, this work aims to bridge the gap between translating assays from microarray analysis (expensive lab-based discovery method) to ISFET arrays (cheap point-of-care diagnostics) providing benefits on tackling infectious disease outbreak and diagnostic testing in hard-to-reach areas of the world.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work has been funded by Rosetrees Trust (grants P78740 and P78699). Mr Moniri is funded by the Engineering and Physical Sciences Research Council Doctoral Training Partnership (EP/N509486/1). Dr Kaforou is funded by the Wellcome Trust (Sir Henry Wellcome Fellowship grant 206508/Z/17/Z). Drs Kaforou, Herberg, and Levin receive support from the National Institute for Health Research Imperial College Biomedical Research Centre (grant DMPED P26077).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The source data are openly available and referred in the manuscript: JAMA. 2016;316(8):835-845. doi:10.1001/jama.2016.11236I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript